Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9382MR)

This product GTTS-WQ9382MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9382MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ322MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ3362MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ15930MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ14786MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ4991MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ5321MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ12599MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ15182MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW